Bone-seeking (osteotropic) drug delivery systems (ODDS) represent an interesting solution for targeting different types of drugs to the bones. In particular, anticancer and antibacterial agents could take advantage of such therapeutic strategy. We have recently developed an innovative approach to this aim: a new osteotropic biomaterial was prepared, based on the conjugation of a poly(lactide- co-glycolide) (PLGA) with the bisphosphonate drug alendronate (PLGA-ALE); its hemo- and cytocompatibility were verified. Starting with this copolymer, an osteotropic nanoparticle system (NP) was produced for the targeted delivery of antineoplastic drugs to osteolytic bone metastases; in particular, doxorubicin was tested as a model drug. The in vitro and in vivo results of the new ODDS are validated in this article. All the experimental data confirmed that the drug retained its activity after loading in the PLGA-ALE NP; they can be thus considered a new promising strategy for active targeting of drugs to bone tissues in different pathological situations.
References
[1]
Basile, L.; Pignatello, R.; Passirani, C. Active targeting strategies for anticancer drug nanocarriers. Curr. Drug Deliv. 2012. in press.
[2]
Hanahan, D.; Weinberg, R.A. The hallmark of cancer. Cell 2000, 100, 57–70, doi:10.1016/S0092-8674(00)81683-9.
[3]
Roodman, G.D. Mechanisms of bone metastasis. N. Engl. J. Med. 2004, 350, 1655–1664, doi:10.1056/NEJMra030831.
[4]
Coleman, R.E. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 2001, 27, 165–176, doi:10.1053/ctrv.2000.0210.
[5]
Taube, T.; Elomaa, I.; Blomqvist, C.; Beneton, M.N.C.; Kanis, J.A. Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone 1994, 15, 161–166, doi:10.1016/8756-3282(94)90703-X.
[6]
Boyde, A.; Maconnachie, E.; Reid, S.A.; Delling, G.; Mundy, G.R. Scanning electron microscopy in bone pathology: Review of methods, potential and applications. Scan. Electron. Microsc. 1986, 4, 1537–1554.
[7]
Guise, T.A.; Mohammad, K.S.; Clines, G.; Stebbins, E.G.; Wong, D.H.; Higgins, L.S.; Vessella, R.; Corey, E.; Padalecki, S.; Suva, L.; Chirgwin, J.M. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin. Cancer Res. 2006, 12, 6213s–6216s, doi:10.1158/1078-0432.CCR-06-1007.
[8]
Houston, S.J.; Rubens, R.D. The systemic treatment of bone metastases. Clin. Orthop. 1995, 312, 95–104.
[9]
Lin, A.; Ray, M.E. Targeted and systemic radiotherapy in the treatment of bone metastasis. Cancer Metastasis. Rev. 2006, 25, 669–675, doi:10.1007/s10555-006-9025-z.
[10]
Iyer, A.K.; Khaled, G.; Fang, J.; Maeda, H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 2006, 11, 812–818, doi:10.1016/j.drudis.2006.07.005.
[11]
Hirsj？rvi, S.; Passirani, C.; Benoit, J.P. Passive and active tumor targeting with nanocarriers. Curr. Drug Discov. Technol. 2011, 8, 188–196, doi:10.2174/157016311796798991.
[12]
Hirabayashi, H.; Fujisaki, J. Bone-specific drug delivery systems: Approaches via chemical modification of bone-seeking agents. Clin. Pharmacokinet. 2003, 42, 1319–1330, doi:10.2165/00003088-200342150-00002.
[13]
Wang, D.; Miller, S.C.; Kopeckova, P.; Kopecek, J. Bone-targeting macromolecular therapeutics. Adv. Drug Del. Rev. 2005, 57, 1049–1076, doi:10.1016/j.addr.2004.12.011.
[14]
Kratz, F. Bisphosphonate-prodrugs. Patent No. WO/2011/023367, 3 March 2011.
[15]
Masarachia, P.; Weinreb, M.; Balena, R.; Rodan, G.A. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 1996, 19, 281–290, doi:10.1016/8756-3282(96)00182-2.
[16]
Coleman, R.E. Metastatic bone disease: Clinical features, pathophysiology, and treatment strategies. Cancer Treat. Rev. 2001, 27, 165–176, doi:10.1053/ctrv.2000.0210.
[17]
Clézardin, P.; Ebetino, F.H.; Fournier, P.G.J. Bisphosphonates and cancer-induced bone disease: Beyond their antiresorptive activity. Cancer Res. 2005, 65, 4971–4974, doi:10.1158/0008-5472.CAN-05-0264.
[18]
Koul, H.K.; Koul, S.; Meacham, R.B. New role for an established drug? Bisphosphonates as potential anticancer agents. Prostate Cancer Prostatic Dis. 2012. in press.
[19]
Fujisaki, J.; Tokunaga, Y.; Takahashi, T.; Hirose, T.; Shimojo, F.; Kagayama, A.; Hata, T. Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. I: Synthesis and in vivo characterization of osteotropic carboxyfluorescein. J. Drug Target 1995, 3, 273–282, doi:10.3109/10611869509015956.
[20]
Wong, R.K.S.; Wiffen, P.J. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst. Rev. 2002, 2, doi:10.1002/14651858.CD002068.
[21]
Zhang, S.; Gangal, G.; Uluda？, H. ‘Magic bullets’ for bone diseases: Progress in rational design of bone-seeking medicinal agents. Chem. Soc. Rev. 2007, 36, 507–531, doi:10.1039/b512310k.
[22]
Bauss, F.; Esswein, A.; Reiff, K.; Sponer, G.; Müller-Beckmann, B. Effect of 17beta-estradiol-bisphosphonate conjugates, potential bone-seeking estrogen pro-drugs, on 17beta-estradiol serum kinetics and bone mass in rats. Calcif. Tissue Int. 1996, 59, 168–173, doi:10.1007/s002239900104.
[23]
Niemi, R.; Vepsalainen, J.; Taipale, H.; Jairvinen, T. Bisphosphonate prodrugs: Synthesis and in vitro evaluation of novel acyloxyalkyl esters of clodronic acid. J Med Chem 1999, 2, 5053–5058.
[24]
MBC Pharma’s Solutions; MBC Pharma: Aurora, CO, USA. Available online: http://www.mbcpharma.com/html/technology.html (last accessed on January 12, 2012).
[25]
Wright, J.E.; Gittens, S.A.; Bansal, G.; Kitov, P.I.; Sindrey, D.; Kucharski, C.; Uluda？, H. A comparison of mineral affinity of bisphosphonate-protein conjugates constructed with disulfide and thioether linkages. Biomaterials 2006, 27, 769–784, doi:10.1016/j.biomaterials.2005.06.012.
[26]
Ogawa, K.; Mukai, T.; Inoue, Y.; Ono, M.; Saji, H. Development of a novel 99mTc-chelate conjugated bisphosphonate with high affinity for bone as a bone scintigraphic agent. J. Nucl. Med. 2006, 47, 2042–2047.
[27]
Tanaka, K.S.; Houghton, T.J.; Kang, T.; Dietrich, E.; Delorme, D.; Ferreira, S.S.; Caron, L.; Viens, F.; Arhin, F.F.; Sarmiento, I.; et al. Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis. Bioorg. Med. Chem. 2008, 16, 9217–9229, doi:10.1016/j.bmc.2008.09.010.
[28]
Tanaka, K.S.; Dietrich, E.; Ciblat, S.; Métayer, C.; Arhin, F.F.; Sarmiento, I.; Moeck, G.; Parr, T.R., Jr.; Far, A.R. Synthesis and in vitro evaluation of bisphosphonated glycopeptide prodrugs for the treatment of osteomyelitis. Bioorg. Med. Chem. Lett. 2010, 20, 1355–1359, doi:10.1016/j.bmcl.2010.01.006.
[29]
McPherson, J.C.; Runner, R.; Buxton, T.B.; Hartmann, J.F.; Farcasiu, D.; Bereczki, I.; R？th, E.; Tollas, S.; Ostorházi, E.; Rozgonyi, F.; Herczegh, P. Synthesis of osteotropic hydroxybisphosphonate derivatives of fluoroquinolone antibacterials. Eur. J. Med. Chem. 2012, 47C, 615–618.
[30]
Wang, D.; Miller, S.; Sima, M.; Kopeckova, P.; Kopecek, J. Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems. Bioconj. Chem. 2003, 14, 853–859, doi:10.1021/bc034090j.
[31]
Satchi-Fainaro, R.; Miller, K.; Shabat, D.; Erez, R. Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases. US Patent 20110142764, 16 June 2011.
[32]
Miller, K.; Erez, R.; Segal, E.; Shabat, D.; Satchi-Fainaro, R. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew. Chem. Int. Ed. Engl. 2009, 48, 2949–2954, doi:10.1002/anie.200805133.
[33]
Bala, I.; Hariharan, S.; Kumar, M.N. PLGA nanoparticles in drug delivery: The state of the art. Crit. Rev. Ther. Drug Carr. Syst. 2004, 21, 387–422, doi:10.1615/CritRevTherDrugCarrierSyst.v21.i5.20.
[34]
Drugs.com: Alendronate. Available online: http://www.drugs.com/pro/alendronate.html (accessed on 12 January 2012).
[35]
DeRuiter, J.; Clark, R. Bisphosphonates: Calcium antiresorptive agents. Revision Spring 2002. Available online: http://www.duc.auburn.edu/~deruija/endo_bisphos.pdf (accessed on July 2011).
[36]
Pignatello, R.; Cenni, E.; Miceli, D.; Fotia, C.; Salerno, M.; Granchi, D.; Avnet, S.; Sarpietro, M.G.; Castelli, F.; Baldini, N. A novel biomaterial for osteotropic drug nanocarriers. Synthesis and biocompatibility evaluation of a PLGA-alendronate conjugate. Nanomedicine 2009, 4, 161–175, doi:10.2217/17435889.4.2.161.
[37]
Cenni, E.; Granchi, D.; Avnet, S.; Fotia, C.; Salerno, M.; Micieli, D.; Sarpietro, M.G.; Pignatello, R.; Castelli, F.; Baldini, N. Biocompatibility of poly(D,L-lactide-co-glycolide) nanoparticles conjugated with alendronate. Biomaterials 2008, 29, 1400–1411, doi:10.1016/j.biomaterials.2007.12.022.
[38]
Salerno, M.; Cenni, E.; Fotia, C.; Avnet, S.; Granchi, D.; Castelli, F.; Micieli, D.; Pignatello, R.; Capulli, M.; Rucci, N.; et al. Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases. Curr. Cancer Drug Targets 2010, 10, 649–659, doi:10.2174/156800910793605767.
[39]
Choi, S.W.; Kim, J.H. Design of surface-modified poly(D,L-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone. J. Control. Release 2007, 122, 24–30, doi:10.1016/j.jconrel.2007.06.003.
[40]
Oberdorster, G.; Maynard, A.; Donaldson, K.; Castranova, V.; Fitzpatrick, J.; Ausman, K.; Carter, J.; Karn, B.; Kreyling, W.; Lai, D.; The ILSI Research Foundation/Risk Science Institute Nanomaterial Toxicity Screening Working Group; et al. Principles for characterizing the potential human health effects from exposure to nanomaterials: Elements for a screening strategy. Part. Fibre Toxicol. 2005, 2, doi:10.1186/1743-8977-2-8.
[41]
Borm, P.J.A.; Robbins, D.; Haubold, S.; Kuhlbusch, T.; Fissan, H.; Donaldson, K.; Schins, R.; Stone, V.; Kreyling, W.; Lademann, J.; et al. The potential risk of nanomaterials: A review carried out for ECETOC. Part. Fibre Toxicol. 2006, 3, doi:10.1186/1743-8977-3-11.
[42]
Cenni, E.; Avnet, S.; Granchi, D.; Fotia, C.; Salerno, M.; Micieli, D.; Sarpietro, M.G.; Pignatello, R.; Castelli, F.; Baldini, N. The effect of poly(D,L-lactide-co-glycolide) nanoparticles conjugated with alendronate on human osteoclast precursors. J. Mat. Sci. Polym. Med. 2011, 7, doi:10.1163/092050611X580373.
[43]
Drugs.com: Doxil. Available online: http://www.drugs.com/pro/doxil.html (accessed on 12 January 2012).
[44]
Andreopoulou, E.; Gaiotti, D.; Kim, E.; Downey, A.; Mirchandani, D.; Hamilton, A.; Jacobs, A.; Curtin, J.; Muggia, F. Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil？): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann. Oncol. 2007, 18, 716–721.
[45]
Momparler, R.L.; Karon, M.; Siegel, S.E.; Avila, F. Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res. 1976, 36, 2891–2895.
[46]
Panyam, J.; Zhou, W.Z.; Prabha, S.; Sahoo, S.K.; Labhasetwar, V. Rapid endo-lysosomal escape of poly(D,L-lactide-co-glycolide) nanoparticles: Implications for drug and gene delivery. FASEB J. 2002, 16, 1217–1226, doi:10.1096/fj.02-0088com.
[47]
Vasir, J.K.; Labhasetwar, V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv. Drug Deliv. Rev. 2007, 59, 718–728, doi:10.1016/j.addr.2007.06.003.
[48]
Clézardin, P.; Ebetino, F.H.; Fournier, P.G.J. Bisphosphonates and cancer-induced bone disease: Beyond their antiresorptive activity. Cancer Res. 2005, 65, 4971–4974, doi:10.1158/0008-5472.CAN-05-0264.
[49]
Santini, D.; Schiavon, G.; Angeletti, S.; Vincenzi, B.; Gasparro, S.; Grilli, C.; La Cesa, A.; Virzí, V.; Leoni, V.; Budillon, A.; et al. Last generation of amino-bisphosphonates (N-BPs) and cancer angio-genesis: A new role for these drugs? Recent Pat. Anticancer Drug Discov. 2006, 1, 383–396, doi:10.2174/157489206778776989.
